A challenge for the success of most targeted therapeutics is to identify prior to therapy those patients with the highest probability of response. For many cancer drugs, the identification of responders is very complicated. 

Merrimack incorporates the development of Companion Diagnostics into the drug discovery process by using Biochemical Network Modeling to identify biomarkers for patient selection and therapeutic response. These biomarkers aid in the pre-clinical development of our therapeutics by identifying the most informative in vitro and in vivo models. Ultimately, we envision incorporating these tools into clinical trial design to enable patient stratification and to accelerate the clinical development process.